yoshida sarcoma

Summary

Summary: An experimental sarcoma of rats.

Top Publications

  1. Hori K, Saito S, Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br J Cancer. 2002;86:1604-14 pubmed
    In a previous study, we used subcutaneous LY80 tumours (a subline of Yoshida sarcoma), Sato lung carcinoma, and methylcholanthrene-induced primary tumours, to demonstrate that a novel water-soluble combretastatin A-4 derivative, AC7700, ..
  2. Goseki N, Yamazaki S, Endo M, Onodera T, Kosaki G, Hibino Y, et al. Antitumor effect of methionine-depleting total parenteral nutrition with doxorubicin administration on Yoshida sarcoma-bearing rats. Cancer. 1992;69:1865-72 pubmed
    ..the combined effect of the methionine-depleting TPN with the administration of doxorubicin was examined in Yoshida sarcoma (YS)-bearing rats with regard to effects on the primary tumor growth, the extension of metastasis, and the ..
  3. Banerji A, Fernandes A. Field bean protease inhibitor preparations, unlike methotrexate, can completely suppress Yoshida sarcoma tumor in rats. Cell Biol Int. 1994;18:1025-34 pubmed
    ..from field bean legume as well as doxorubicin and cyclophosphamide could effectively suppress the growth of Yoshida sarcoma ascites tumor cells transplanted in adult rats and prevent their death...
  4. Nagahama T, Goseki N, Endo M. Doxorubicin and vincristine with methionine depletion contributed to survival in the Yoshida sarcoma bearing rats. Anticancer Res. 1998;18:25-31 pubmed
    ..fraction of labeled mitosis, within 3 to 4 days after the introduction of Met-deplete TPN in the ascites type Yoshida sarcoma (YS) -bearing rats, the cell cycle of the tumor cells showed marked delay and the fraction of labeled mitosis ..
  5. Tsuchiya H, Tsuchiya Y, Kobayashi T, Kikuchi Y, Hino O. Isolation of genes differentially expressed between the Yoshida sarcoma and long-survival Yoshida sarcoma variants: origin of Yoshida sarcoma revisited. Jpn J Cancer Res. 1994;85:1099-104 pubmed
    The Yoshida sarcoma (YS) is characterized by growth as "free cells" in ascites...
  6. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004-9 pubmed
    ..On p.o. administration of 5-FU (2 mg/kg) and a potent inhibitor of 5-FU degradation to Yoshida sarcoma-bearing rats, oxonic acid (10 mg/kg) was found to inhibit the formation of 5-fluorouridine-5'-monophosphate ..
  7. Fujii S, Fukushima M, Shimamoto Y, Shirasaka T. Pharmacokinetic modulation of plasma 5-fluorouracil concentrations to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil. Jpn J Cancer Res. 1989;80:509-12 pubmed
    ..to increase antitumor activity during continuous venous infusion (CVI) of low doses of 5-FU were examined in Yoshida sarcoma-bearing rats...
  8. Sevaljevic L, Savovski K, Sekularac S. The effect of Yoshida sarcoma cell transplantation to rats on the rate of acute-phase protein synthesis in the liver. Carcinogenesis. 1991;12:1601-6 pubmed
    The effect of transplantation of Yoshida sarcoma cells into rats on the concentrations of both the acute-phase proteins (APPs) in the serum and their mRNAs in the liver has been investigated...
  9. Busquets S, Alvarez B, van Royen M, Carbó N, Lopez Soriano F, Argiles J. Lack of effect of the cytokine suppressive agent FR167653 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett. 2000;157:99-103 pubmed
    ..Nor did the administration of FR167653 influence tumour growth. It is concluded that the drug is unable to reverse the cachectic state in this particular experimental tumour model. ..

More Information

Publications93

  1. Tanda S, Hori K, Saito S, Zhang Q, Li H, Suzuki M. Effects of intravenous infusion of dopamine on tumor blood flow in rat subcutis. Jpn J Cancer Res. 1994;85:556-62 pubmed
    ..TBF), we measured the blood flow of normal subcutaneous tissue and subcutaneous tumor (LY-80, a variant of Yoshida sarcoma) in enflurane-anesthetized male Donryu rats using a hydrogen clearance method...
  2. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol. 1993;32:167-72 pubmed
    ..of exogenous L-methionine into ascitic tumor cells and increased the levels of CH2FH4 and FH4 in ascitic Yoshida sarcoma and P-388 cells transplanted into rats and mice to levels about 2-3 times those measured in cells from ..
  3. Tokuda K, Natsugoe S, Shimada M, Kumanohoso T, Yoshizawa H, Uemura Y, et al. [Experimental study of cisplatin microspheres incorporated in polylactic acid and polyethylene glycol acid on peritoneal carcinomatosis in rats]. Gan To Kagaku Ryoho. 1996;23:1516-8 pubmed
    ..CDDP-SOL, empty-MS and non-therapy group on survival time were compared using intraperitoneally administered Yoshida sarcoma. The survival time in CDDP-MS, CDDP-SOL, non-therapy and empty-MS group were 43 +/- 24, 11.7 +/- 4.7, 9...
  4. Bacher G, Nickel B, Emig P, Vanhoefer U, Seeber S, Shandra A, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res. 2001;61:392-9 pubmed
  5. Sugimoto Y, Matsuo K, Takeda S, Yamada Y, Tsukagoshi S. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)]. Gan To Kagaku Ryoho. 1990;17:353-8 pubmed
    ..L 1210 leukemia, P 388 leukemia, colon 38 adenocarcinoma, B 16 melanoma), LX-1 human tumor xenografts, and Yoshida sarcoma in rat...
  6. Pawse A, Tarachand U. Characterization of urokinase-type plasminogen activator of rat decidual tissue. Biochem Mol Biol Int. 1994;33:775-84 pubmed
    ..in rabbit and a monospecific antiserum raised against it does not cross react with human melanoma tPA or rat Yoshida sarcoma tPA but elicits a precipitin reaction with human uPA and extracts of rat placenta and kidney...
  7. Nowicky J, Hiesmayr W, Nowicky W, Liepins A. Influence of Ukrain on DNA, RNA and protein synthesis in malignant cells. Drugs Exp Clin Res. 1996;22:81-91 pubmed
    ..YAC-1, P815 and human WiDr cells. Ukrain inhibits the DNA, RNA and protein synthesis in malignant cell lines at relatively high concentrations and to a small extent in normal cells. ..
  8. Jahde E, Roszinski S, Volk T, Glüsenkamp K, Wiedemann G, Rajewsky M. Metabolic response of AH13r rat tumours to cyclophosphamide as monitored by pO2 and pH semi-microelectrodes. Eur J Cancer. 1992;29A:116-22 pubmed
  9. Metodiewa D, Kochman A, Koceva Chyła A. Anticancer potential of N,N-diethylaminoethyl ethers of flavanone oximes: a comparison with mitoxantrone action on rat Yoshida sarcoma cells in vivo. Anticancer Res. 1999;19:1249-54 pubmed
    ..anticancer abilities of four biologically active N,N-diethylaminoethyl ethers of flavanone oximes against rat Yoshida Sarcoma cells in vivo, and to investigate the mechanism(s) involved...
  10. Araki H, Fukushima M, Kamiyama Y, Shirasaka T. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett. 2000;160:185-91 pubmed
    ..When CDDP (1 mg/kg) was administered i.p. to ascitic Yoshida sarcoma-bearing rats for 4 consecutive days, both the reduced folate levels and methionine synthase activity in the ..
  11. Hagiwara A, Takahashi T, Iwamoto A, Yoneyama C, Itoh M, Sasabe T. Affinity of intraperitoneally injected activated carbon particles adsorbing mitomycin C to tumor surface of Yoshida sarcoma. Anticancer Drug Des. 1990;5:359-69 pubmed
    ..intraperitoneally to male rats of Donryu strain transplanted intraperitoneally with 10(7) cells/rat of Yoshida sarcoma 4 days before injection. The rats were subjected to autopsy within 60 min after injection...
  12. Wolters U, Brenner U, Muller J, Wolf K. [Does parenteral linoleic acid modify tumor growth? Studies with the Yoshida sarcoma model]. Langenbecks Arch Chir. 1991;376:257-63 pubmed
    ..study with sprague-dawley-rats we tested the effect of parenteral substituted LCT-fats on tumor growth of the Yoshida sarcoma in its ascites form. Therefore we tested 4 groups with 10 tumor-bearing and 10 non-tumor-bearing rats...
  13. Dubin M, Fernandez Villamil S, Stoppani A. [Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]. Medicina (B Aires). 2001;61:343-50 pubmed
    ..Diaphorase and NAD(P)H-quinone reductase, which catalyse beta-lap redox-cycling and ROS production, seem to play an essential role in beta-lap activity. On these grounds, clinical applications of beta-lap have been suggested. ..
  14. Fimiani V, Richetti A. Antitumor effect of a mycotoxin: rubratoxin B. Chemotherapy. 1993;39:59-62 pubmed
    ..The differences between in vitro and in vivo results can be explained by a rapid neutralization of the drug on behalf of the organism's enzymes or by being bound to proteins and peritoneal cells unlike tumor cells. ..
  15. Carbó N, Lopez Soriano J, Costelli P, Busquets S, Alvarez B, Baccino F, et al. Interleukin-15 antagonizes muscle protein waste in tumour-bearing rats. Br J Cancer. 2000;83:526-31 pubmed
  16. Savovski K, Pujic N, Vranic V, Dimitrijevic B. Effects of a modified CMF treatment (cyclophosphamide, methotrexate and 5-fluorouracil) on hematopoietic tissues and Yoshida sarcoma in rats. Acta Oncol. 1994;33:793-8 pubmed
    ..The study was done on Wistar rats bearing Yoshida sarcoma in the ascites form...
  17. Koceva Chyła A, Kochman A, Głebska J, Gwozdzinski K, Jozwiak Z, Metodiewa D. Tempicol-3, a novel piperidine-N-oxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo. Anticancer Res. 2000;20:4611-8 pubmed
    ..as an antitumor agent in vivo was also investigated in a pharmacological test, using rats bearing 3-day old Yoshida Sarcoma (promotion phase of the disease)...
  18. Nakazawa I, Iwaizumi M. A role of the cancer cell membrane fluidity in the cancer metastases: an ESR study. Tohoku J Exp Med. 1989;157:193-8 pubmed
    AH66F or Yoshida sarcoma (YS) cells were transplanted intraperitoneally into male Donryu rats. Cancer cells obtained from ascites were suspended in saline solution (10(7) cells/ml) after washing. Then, 0...
  19. Abe Y, Imamura K, Ogawa Y, Tsujinaka T, Kobayashi M, Yano M, et al. Tumor-derived components were responsible for suppression of ornithine decarboxylase activity in the rat wounded skin. J Surg Oncol. 1994;55:135-42 pubmed
    To elucidate the principal cause of delayed wound healing in a tumor-bearing host, the effect of Yoshida sarcoma-derived components on dermal wound healing was investigated in rats with the aid of ornithine decarboxylase (ODC) activity ..
  20. Seifert R, Hoshino J, Kroger H. Nicotinamide methylation. Tissue distribution, developmental and neoplastic changes. Biochim Biophys Acta. 1984;801:259-64 pubmed
    ..The highly malignant Zajdela hepatoma, Yoshida sarcoma, sarcoma 180 and Ehrlich ascites tumor methylated nicotinamide only at a negligibly low rate...
  21. Fukushima M. [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. Gan To Kagaku Ryoho. 2006;33 Suppl 1:19-26 pubmed
    ..Throughout our preclinical antitumor studies of S-1, alone and/or in combination with other anticancer drugs, it would be expected to contribute greatly to the treatment of cancer patients. ..
  22. Metodiewa D, Kochman A, Skolimowski J, Koceva Chyła A. TTT, a novel free radical spin trap, induces apoptosis in sarcoma Yoshida cells in vivo: comparative investigations of its cytotoxicity in vitro. Anticancer Res. 1999;19:3343-8 pubmed
    ..We found that TTT inhibits the growth and proliferation of two immortalized cell types-hamster B14 cell line and mouse NIH 3T3 fibroblasts which we used as a model for neoplastic phenotype, in a dose-dependent manner. ..
  23. McCarthy H, McKibbin P, Perkins A, Linton E, Williams G. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol. 1993;264:E638-43 pubmed
    ..stimulant and an inhibitor of feeding behavior, were investigated in hypothalamic nuclei in rats carrying the Yoshida sarcoma. Tumor-bearing rats (n = 10), non-tumor-bearing controls (n = 10), and food-restricted rats (n = 10), which ..
  24. Yoshida S, Ishibashi N, Noake T, Shirouzu Y, Oka T, Shirouzu K. Glutamine and arginine metabolism in tumor-bearing rats receiving total parenteral nutrition. Metabolism. 1997;46:370-3 pubmed
    ..Male Donryu rats (N = 36; body weight, 200 to 225 g) were divided into two groups, control and TB rats. Yoshida sarcoma cells (1 x 10(6)) were inoculated into the back of the rats (n = 18) subcutaneously on day 0...
  25. Kumanohoso T, Natsugoe S, Shimada M, Aikou T. Enhancement of therapeutic efficacy of bleomycin by incorporation into biodegradable poly-d,l-lactic acid. Cancer Chemother Pharmacol. 1997;40:112-6 pubmed
    ..of BLM-PLA and BLM-SOL on tumor growth were compared with no treatment using a subcutaneously transplanted Yoshida sarcoma. The antitumor effect of BLM-PLA was significantly higher than that of BLM-SOL and no treatment...
  26. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J. Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv. 2009;6:255-60 pubmed
    ..The purpose of this study was to establish a model for investigating the depot time of particles injected into tumors in relation to tumor vascularization and particle size...
  27. Harada M, Nishitani H, Shirahama T, Koga K, Miura I. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors]. Gan To Kagaku Ryoho. 1991;18:75-80 pubmed
    ..In this study, two kinds of tumors were used, i.e., Yoshida sarcoma implanted subcutaneously to the abdomen of rats and drug-induced tumors in the rats livers...
  28. Letnansky K, Vetterlein M, Shi C. Inhibition of DNA synthesis and oncogene expression in tumor cells by the biological factor DIF. Anticancer Res. 1991;11:981-6 pubmed
    ..On of the main consequences of DIF action is the inhibition of c-fos and c-myc expression and/or degradation...
  29. Fahrig R, Heinrich J, Nickel B, Wilfert F, Leisser C, Krupitza G, et al. Inhibition of induced chemoresistance by cotreatment with (E)-5-(2-bromovinyl)-2'-deoxyuridine (RP101). Cancer Res. 2003;63:5745-53 pubmed
    ..Because of these beneficial properties of BVDU, a clinical pilot Phase I/II study with five human tumor entities has been started at the University of Dresden (Dresden, Germany). So far, no unwanted side effects have been observed...
  30. Groscolas R, Oudart H, Bougnoux P, Lhuillery C. Developing Yoshida sarcoma does not influence the fatty acid composition of adipose tissues in the rat. Nutr Cancer. 1995;24:77-84 pubmed
    ..We used a rodent model of transplanted solid tumor (Yoshida sarcoma) and measured the fatty acid composition from different adipose sites in the absence and in the presence of ..
  31. Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, et al. Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs. 1998;9:817-23 pubmed
    ..Almost complete inhibition of the tumor growth was obtained on 7 day schedules in Yoshida sarcoma-bearing rats by consecutive administration of 30 mg/kg/day of oral S-1 and 40 mg/kg/day infusion of 5-FU...
  32. Trebichavsky I, Mara M, Sinkora J, Splichal I, Stepankova R. Immunomodulatory effects of Bacillus firmus. Folia Microbiol (Praha). 1997;42:403-8 pubmed
    ..B. firmus induced antitumor immunity in rats with transplanted Yoshida sarcoma cells. Granular lymphocytes and dead tumor cells were found in peritoneal exudate of stimulated animals. B...
  33. Busquets S, Figueras M, Fuster G, Almendro V, Moore Carrasco R, Ametller E, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 2004;64:6725-31 pubmed
  34. Zakhariev S, Golovinsky E, Stoev S, Maneva L, Aleksiev B. [Synthesis and antitumor action of N,N-di(2-chlorethyl)-hydrazines of alpha-aminocarboxylic acid antimetabolites]. Pharmazie. 1989;44:542-4 pubmed
    ..Preliminary studies of the activity on experimental tumour models were carried out. It was shown that these compounds have a high antitumour effect (80-100%) on sarcoma Yoshida and carcinosarcoma Walker...
  35. Metodiewa D, Kochman A, Gebicka L, Skolimowski J. Evidence for peroxidative oxidation of substituted piperidine nitroxides, acting as apoptosis inducers in Yoshida Sarcoma cells in vivo. Anticancer Res. 2000;20:2421-6 pubmed
    ..An in vivo study ("Screening test of chemicals employing Yoshida Sarcoma animals") was carried out to verify whether the structure and/or the chain length of substituent of ..
  36. Mangano A, Nobile G. [Complement behavior in rats bearing Yoshida tumors subjected to treatment with gonadotropin and PGE2]. Boll Soc Ital Biol Sper. 1991;67:295-302 pubmed
  37. Ando A, Ando I, Sanada S, Hiraki T, Takeuchi T, Hisada K, et al. Relationship between the biodistributions of radioactive metal nuclides in tumor tissue and the physicochemical properties of these metal ions. Ann Nucl Med. 1999;13:83-8 pubmed
    ..We therefore conclude that the biodistribution of radioactive metal ions in tumor tissue is determined by its own physicochemical properties...
  38. Hill W, McAuliffe C, Sharma H, Zaki A. Synthesis, characterization and anti-tumour testing of some platinum(II) amine complexes containing 1,1- and 1,2-cyclobutanedicarboxylate ligands. Chem Biol Interact. 1990;73:337-51 pubmed
    ..The Yoshida lymphoscarcoma screen, usually insensitive to platinum drugs, was found to respond well to [Pt(n-C4H9NH2)2(1,1-CBDCA)] in 5-day subcutaneously implanted tumours in female Wistar rats...
  39. Bols M, Binderup L, Hansen J, Rasmussen P. Synthesis and collagenase inhibition of new glycosides of aranciamycinone: the aglycon of the naturally occurring antibiotic aranciamycin. Carbohydr Res. 1992;235:141-9 pubmed
    ..The new glycosides were tested for inhibition of Clostridium histolyticum collagenase and Yoshida Sarcoma tumor cells.
  40. Strnad V, Kamprad F, Jahns J, Madaj Sterba P, Kirschner M, Meyer M, et al. [Hypoxyradiotherapy: changes in the oxygen partial pressure distribution in the tumor and in the healthy tissue under acute respiratory hypoxia]. Strahlenther Onkol. 1996;172:427-33 pubmed
    ..Based on the oxygen effect a new therapeutic modality has been developed to protect healthy tissues while breathing hypoxic gas mixture during irradiation...
  41. Kalraiya R, Sanjay A, Mehta N. Isolation of a glycoprotein responsible for the enhanced concanavalin A agglutinability of erythrocytes in Yoshida-ascites-sarcoma-bearing rats: the mechanism of paraneoplastic syndromes. Biochem J. 1993;292 ( Pt 1):163-70 pubmed
    ..The study unequivocally demonstrates that a protein from the tumour fluid can appear in the circulation, interact with host cells that are not in contact with the tumour and modify their properties...
  42. Crosby L, Bistrian B, Ling P, Istfan N, Blackburn G, Hoffman S. Effects of branched chain amino acid-enriched total parenteral nutrition on amino acid utilization in rats bearing Yoshida sarcoma. Cancer Res. 1988;48:2698-702 pubmed
    ..c. Yoshida sarcoma (n = 15) or sham implantations (n = 18)...
  43. Rassweiler J, Prager P, Haferkamp A, Alken P, Kauffmann G, Richter G. Transarterial nephrectomy: the current status of experimental and clinical studies. J Endourol. 2008;22:767-82 pubmed publisher
    ..This paper focuses on the different principles of vaso-occlusion and further improvements of the technique such as capillary chemoembolization in experimental as well as clinical studies...
  44. Kumanohoso T, Natsugoe S, Tokuda K, Shimada M, Sagara M, Shinkawa T, et al. [Drug distribution and antitumor effect of bleomycin incorporated in poly DL-lactic acid in rats]. Gan To Kagaku Ryoho. 1994;21:2248-50 pubmed
    ..BLM-PLA, BLM-SOL and nontreatment on tumor growth and survival time were compared using subcutaneous tumor of Yoshida sarcoma in 21 rats each...
  45. Hori K, Nishihara M, Yokoyama M. Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: macromolecular delivery according to tumor vascular growth stage. J Pharm Sci. 2010;99:549-62 pubmed publisher
    ..Our results suggest that we must develop a novel therapeutic strategy that can deliver sufficient nanomedicine to microtumors...
  46. Meijsing B, Carbó N, Lopez Soriano F, Argiles J. Effects of the phosphodiesterase-IV inhibitor EMD 95832/3 on tumour growth and cachexia in rats bearing the Yoshida AH-130 ascites hepatoma. Cancer Lett. 2002;188:53-8 pubmed
    ..It is concluded that the drug is unable to reverse the cachectic state in this particular experimental tumour model...
  47. Ohta S, Sato S, Saito Y, Fukushi A. [Experimental study on antitumor effect of cisplatin-microcapsule]. Nihon Sanka Fujinka Gakkai Zasshi. 1993;45:205-12 pubmed
    ..6) The above results suggested that CDDP-mc is clinically applicable to the treatment of ovarian cancer and uterine cancer when administered intraperitoneally and locally (intra-tumor)...
  48. Tayek J, Blackburn G, Bistrian B. Alterations in whole body, muscle, liver, and tumor tissue protein synthesis and degradation in Novikoff hepatoma and Yoshida sarcoma tumor growth studied in vivo. Cancer Res. 1988;48:1554-8 pubmed
    ..in vivo was assessed in tumor tissue, skeletal muscle, liver, and the whole body of rats bearing either the Yoshida sarcoma or Novikoff hepatoma after 18 days of tumor growth and compared to tumor-free controls...
  49. Wolters U, Muller J, Wölfelschneider K, Iffland H. [Does varied parenteral zinc administration modify interaction between tumor and host? Studies based on an animal model]. Infusionstherapie. 1991;18:123-8 pubmed
    ..We found a weight loss of the NTBR with zinc substitution. Zinc improves the synthesis of the tumor and leads to a weight loss of the host in our animal model...
  50. Harada M, Nishitani H, Shiramhama T, Koga K, Miura I. [Index of tumor response by in-vivo 31P-MRS--T1 effect as a new predicting index of therapeutic effects]. Nihon Gan Chiryo Gakkai Shi. 1990;25:1482-6 pubmed
    We observed the metabolism of the Yoshida sarcoma by in-vivo 31P-MRS, using two varieties of repetition time (TR), i.e., TR2s and TR10s. It was measured before the injection of 5FU and 4, 24, 48 hours after the injection...
  51. Kamat J. Nicotinamide-induced modification of hepatic MFO systems in tumour-bearing rats, treated with anti-cancer drugs. Cancer Lett. 1996;109:85-90 pubmed
    ..wt.) could effectively restore the hepatic drug metabolising enzyme levels back to control values in tumour-bearing animals treated with cyclophospamide and 5-fluorouracil...
  52. Miyauchi S, Imaoka T, Utsunomiya T, Hayashi K, Kubo M, Kawaguchi T, et al. Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels. Jpn J Cancer Res. 1994;85:665-8 pubmed
    A new tumor model was developed in which solid Yoshida sarcoma tissue injected intravenously developed into tumors in the lungs of about 30% (13/42) of the inoculated rats...
  53. Mangano A, Turnaturi M, Floridia V, Cosenza C, Condorelli F, Foti L. Fetal antigens as tumor growth enhancing factors in Yoshida's tumor rats. Boll Soc Ital Biol Sper. 1990;66:1105-12 pubmed
    ..Therefore, fetal antigens are likely able to carry out an immunosuppressive action. The fact that they appear on neoplastic cells could be seen as a metabolic modification effect or as a growth enhancing factor...
  54. Goto T, Tomizawa N, Kobayashi E, Fujimura A. A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model. J Pharmacol Sci. 2004;95:163-73 pubmed
    We prepared a colon cancer-bearing Yoshida sarcoma rat model to examine the dose-response relationship of antitumor activity of intracolonically or orally administered 5-fluorouracil (5-FU; 45, 30, 20, 13, and 8 mg/kg)...
  55. Oudart H, Heitz A, Bnouham M, Malan A, Le Maho Y. Body protein and lipid deficit in tumour-bearing rats in relation to age. Br J Cancer. 1993;68:885-9 pubmed
    ..is influenced by aging as in uncomplicated starvation, we compared the difference of body composition between Yoshida sarcoma bearing rats and young (200 g, 7 weeks) and adult (400 g, 13 weeks) control rats...
  56. Ando A, Ando I, Hiraki T, Yamada N, Hisada K. Determination of the lysosomal role in tumor accumulation of 67Ga by dual-tracer studies. Int J Rad Appl Instrum A. 1989;40:521-4 pubmed
    ..In addition, it was revealed that tumor lysosome was hardly disrupted at all in some phases of fractionation procedures...
  57. Goseki N, Endo M, Onodera T, Kosaki G. Anti-tumor effect of L-methionine-deprived total parenteral nutrition with 5-fluorouracil administration on Yoshida sarcoma-bearing rats. Ann Surg. 1991;214:83-8 pubmed
    ..combined effect of the methionine-deprived TPN with administration of 5-fluorouracil (5-FU) was examined in Yoshida Sarcoma (YS)-bearing rats, from aspects of effects on the tumor metastasis and the host animal's life span, in the ..
  58. Kutscher B, Niemeyer U, Engel J, Kleemann A, Hilgard P, Pohl J, et al. Synthesis and antitumor activity of two ifosfamide analogs with a five-membered ring. Arzneimittelforschung. 1995;45:323-6 pubmed
    ..The observed low biological activity gives evidence that both, the six-membered oxazaphosphorinane ring and the two N-2-chloroethyl-side chains are necessary for the generation of the ultimate alkylator, i.e. the ifosfamide mustard 5...
  59. Kallinowski F, Vaupel P. pH distributions in spontaneous and isotransplanted rat tumours. Br J Cancer. 1988;58:314-21 pubmed
    ..It is concluded that pathology-related variations of tumour pH may be more important than the mode of tumour origin or the degree of malignancy...
  60. Bergamini C, Signorini M, Caselli L, Melandri P. Regulation of transglutaminase activity by GTP in digitonin permeabilized Yoshida tumor cells. Biochem Mol Biol Int. 1993;30:727-32 pubmed
    ..GTP inhibits protein labelling at low calcium concentration by inhibiting type 2 TGase without affecting membrane-bound TGase. These results support the notion that inhibition of type 2 TGase by GTP is physiologically relevant...
  61. Ando A, Ando I. Biodistributions of radioactive bipositive metal ions in tumor-bearing animals. Biometals. 1994;7:185-92 pubmed
    ..Lysosome did not play an important role in the accumulation of 65Zn, 85Sr and 103Pd into tumor and liver...
  62. Omura K, Hashimoto T, Kawakami K, Kanehira E, Watanabe T, Hirano K, et al. [Innate resistance to thymidylate synthase inhibition after 5-fluorouracil treatment--a rationale of combined use of cisplatin and its optimal administration dose]. Gan To Kagaku Ryoho. 1994;21:2007-11 pubmed
    We examined the changes of the number of FdU MP binding sites of thymidylate thynthase (TS-BS) in Yoshida sarcoma after administration of 5-FU to the tumor bearing rats...
  63. Sadahiro S, Suzuki T, Ishikawa K, Nakamura T, Saguchi T, Kamijo A, et al. Preliminary study of the optimal dosing schedule for oral UFT/leucovorin chemotherapy. Anticancer Res. 2004;24:625-30 pubmed
    We evaluated the optimal dosage schedule for combined oral chemotherapy using uracil/tegafur (UFT) and leucovorin (LV) in Yoshida sarcoma-bearing rats.
  64. Hibino Y, Kawarabayashi Y, Kohri H, Ueda N, Tsukagoshi S. [The mechanism of potentiation of the antitumor effect of 5-fluorouracil by methionine-free intravenous amino acid solution (AO-90) in rats]. Gan To Kagaku Ryoho. 1994;21:2021-8 pubmed
    ..5-fluorouracil (5-FU) when concomitantly used as the nitrogen source in total parenteral nutrition (TPN) in Yoshida sarcoma (YS)-bearing rats...
  65. Tan Y, Xu M, Guo H, Sun X, Kubota T, Hoffman R. Anticancer efficacy of methioninase in vivo. Anticancer Res. 1996;16:3931-6 pubmed
    ..Methioninase injected i.p. arrested the growth of the Yoshida sarcoma in nude mice and greatly slowed the growth of the H460 human non-small-cell-lung carcinoma in nude mice...
  66. Guo H, Tan Y, Kubota T, Moossa A, Hoffman R. Methionine depletion modulates the antitumor and antimetastatic efficacy of ethionine. Anticancer Res. 1996;16:2719-23 pubmed
    ..that the methionine analog ethionine is synergistic with methionine depletion in arresting the growth of the Yoshida sarcoma both in vitro and when transplanted to nude mice...
  67. Pestonjamasp V, Mehta N. Erythrocytes from Yoshida ascites sarcoma-bearing rats have reduced surface charge: the effect of tumor products. Cancer Biochem Biophys. 1995;15:19-23 pubmed
    ..01). Thus the modification of the host cell surface observed in tumor-bearing rats arises due to non-specific binding of tumor products that reduce the host cell surface charge...
  68. Ando A, Ando I, Katayama M, Sanada S, Hiraki T, Mori H, et al. Biodistributions of radioactive alkaline metals in tumor bearing animals: comparison with 201Tl. Eur J Nucl Med. 1988;14:352-7 pubmed
    ..Therefore, suitable radionuclides of K and K analogs can be excellent agents for visualization of viable tumor tissues...
  69. Mendez B, Ling P, Istfan N, Babayan V, Bistrian B. Effects of different lipid sources in total parenteral nutrition on whole body protein kinetics and tumor growth. JPEN J Parenter Enteral Nutr. 1992;16:545-51 pubmed
  70. Savage D, Emminger A, Mohr U. A novel class of antitumour agents. I. Chemistry and animal experiments. Cancer Lett. 1977;2:267-72 pubmed
    ..Intragastric and intraperitoneal application of DAP caused side effects suggesting a local toxicity...
  71. Busquets S, Fuster G, Ametller E, Olivan M, Figueras M, Costelli P, et al. Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clin Nutr. 2007;26:239-44 pubmed
    ..We decided to investigate the potential anti-wasting properties of resveratrol on different models of cancer cachexia in experimental animals...
  72. Li S, Ando A, Ando I. Effects of glutamate dehydrogenase, choline oxidase, and glucose-6-phosphatase on 67Ga accumulation in lysosome. Zhongguo Yao Li Xue Bao. 1995;16:51-3 pubmed
    ..To clarify the effects of the activities of hepatic enzymes in liver, hepatoma, and malignant tumor on 67Ga accumulation in lysosome...
  73. Combaret L, Tilignac T, Claustre A, Voisin L, Taillandier D, Obled C, et al. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats. Biochem J. 2002;361:185-92 pubmed
    ..Taken together, the data indicate that HWA 448 is a powerful inhibitor of muscle wasting that blocks enhanced Ub-proteasome-dependent proteolysis in situations where TNF production rises, including cancer and sepsis...
  74. Fimiani V, Minniti D. Anti-tumor properties of the organometallic complex cis-dimethylbis[sulfinylbis[methane]-S]platinum(II). Anticancer Drugs. 1992;3:9-15 pubmed
    ..A comparison between the therapeutic properties of the title complex with those of cis-[PtCl2(NH3)2] (CDDP) reveals that cis-dimethyl platinum(II) exhibits the same anti-tumor activity associated with 6 times reduced toxicity...
  75. Kalraiya R, Iyer S, Chati A, Mehta N. Mechanism of host cell membrane modification by tumour: a model for paraneoplastic syndromes. Indian J Biochem Biophys. 1990;27:460-3 pubmed
    ..The protein has a molecular weight of 600 kDa in the native state and a pI of 5.35. It is made up of 4 identical subunits of Mr 170,000. It is detected in the plasma of tumour-bearing but not normal rats.(ABSTRACT TRUNCATED AT 250 WORDS)..
  76. Melandri P, Benassi G, Ventrelli I. [Growth of the Yoshida ascites/hepatoma in co-culture with rat fibroblasts]. Boll Soc Ital Biol Sper. 1990;66:1129-35 pubmed
    ..Adding minced polyester surgical thread (Mersilene - M) into the co-cultures slowed down the growth of Y to some extent, yet no evidence has been obtained of toxic compounds released by M...
  77. Shirasaka T, Shimamoto Y, Kato T, Fukushima M. [Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil]. Gan To Kagaku Ryoho. 1998;25:371-84 pubmed
    ..FT, like the case in continuous infusion of 5-FU, which resulted in an augmentation of antitumor efficacy in Yoshida sarcoma-bearing rats, although severe GI toxicity simultaneously occurred...
  78. Nogusa H, Yano T, Kajiki M, Gonsho A, Hamana H, Okuno S. Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates. Biol Pharm Bull. 1997;20:1061-5 pubmed
    ..These conjugates were also more effective than DXR in rats bearing Yoshida sarcoma. However, CMPul-DXR conjugate bound through Gly-Gly-Gly-Gly was less effective against Walker 256-bearing ..
  79. Stepankova R, Mara M, Ocenaskova J. Prolonged survival of AVN Wistar rats with transplanted Yoshida sarcoma and increase of granular lymphocytes after administration of Bacillus firmus and their crude lipids. Folia Microbiol (Praha). 1995;40:413-6 pubmed
    ..extraction of cell suspension with chloroform-methanol to rats, strain AVN Wistar, transplanted later with Yoshida sarcoma, significantly prolonged the survival of the animals in comparison with the control group...
  80. Guo H, Lishko V, Herrera H, Groce A, Kubota T, Hoffman R. Therapeutic tumor-specific cell cycle block induced by methionine starvation in vivo. Cancer Res. 1993;53:5676-9 pubmed
    ..present study we have achieved this goal of inducing a tumor-specific cell cycle block in vivo by depriving Yoshida sarcoma-bearing nude mice of dietary methionine...
  81. Kubota T, Matsui K, Ohtani M, Takasaki S. [Local chemotherapy by a sustained-release preparation with fibrin seal against the operative wound in head and neck cancer]. Gan To Kagaku Ryoho. 1995;22:877-82 pubmed
    ..The drug release rate in this therapy in vitro study was 50% after 24 hrs. When injected to rats bearing Yoshida sarcoma, it exhibited a marked antitumor effect compared to the control group given 5-FU alone...
  82. Sato H, Hori K, Sugiyama K, Tanda S, Sato Y. [Tumor microcirculation and selective enhancement of drug delivery--clinical applications based on pathophysiological experiments]. Gan To Kagaku Ryoho. 2000;27:1191-200 pubmed
    ..Among the experimental evidence using Yoshida Sarcoma and Ascites Hepatomas, functional differences in microcirculation between tumor and normal tissues were found ..
  83. Sanjay A, Kalraiya R, Mehta N. Modification of the erythrocyte surface in rats bearing Yoshida ascites sarcoma is brought about by a tumour variant of alpha2-macroglobulin. Biochem J. 1997;322 ( Pt 2):379-84 pubmed
    ..The modification of the host cell surface in the tumour-bearing rats is thus caused by what appears to be a tumour (oncofetal?) variant of alpha2-macroglobulin...
  84. Ito K, Ye C, Kondou K, Akiyama S, Takagi H, Hirota H, et al. [Treatment of solid tumor by a small amount of direct current]. Gan To Kagaku Ryoho. 1995;22:1647-51 pubmed
    ..Solid tumors of Yoshida sarcoma in Donryu rat were treated by 1 mA of constant direct current for 1 hour a day, for 4 days...